Definium Therapeutics (NASDAQ:DFTX) Issues Quarterly Earnings Results, Misses Expectations By $0.23 EPS

Definium Therapeutics (NASDAQ:DFTX) announced its earnings results on Thursday. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23), FiscalAI reports.

Here are the key takeaways from Definium Therapeutics’ conference call:

• Three pivotal DT120 ODT phase III readouts are imminent — EMERGE (MDD) top-line later this quarter, and VOYAGE and PANORAMA (both GAD) expected in early and late Q3 respectively, with Breakthrough Therapy designation for DT120 in GAD and an NDA submission planned subject to positive data.
• All pivotal trials are near complete (EMERGE 149 enrolled; VOYAGE 214; PANORAMA >200) and were powered around a 5‑point placebo‑adjusted difference (VOYAGE/PANORAMA >99% power; EMERGE 80% with ~3‑point significance threshold), which management says targets clinically meaningful and durable single‑dose effects.
• Each study includes a Part B with up to one year of follow‑up and up to four open‑label retreatments triggered at moderate symptoms, intended to characterize retreatment patterns, durability, and longer‑term safety for potential labeling discussions.
• The company ended Q1 with $373.4 million in cash and investments, which management believes provides runway to fund planned operations through multiple pivotal readouts and into 2028.
• Near‑term spend ramped materially — Q1 R&D rose to $41.5M and G&A to $17.7M versus prior year — contributing to a wider net loss of $77.1M, with a $20M quarterly impact from warrant fair‑value movement, indicating higher cash burn and elevated execution costs ahead.

Definium Therapeutics Price Performance

Definium Therapeutics stock traded down $1.15 during midday trading on Friday, hitting $22.05. The company’s stock had a trading volume of 2,203,452 shares, compared to its average volume of 1,963,772. Definium Therapeutics has a 12 month low of $6.03 and a 12 month high of $26.25. The company has a quick ratio of 6.29, a current ratio of 6.29 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $2.20 billion, a PE ratio of -8.86 and a beta of 2.37. The stock’s 50-day moving average price is $19.98 and its 200-day moving average price is $16.05.

Institutional Trading of Definium Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DFTX. Russell Investments Group Ltd. boosted its holdings in Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Definium Therapeutics by 56.0% in the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after buying an additional 3,020 shares in the last quarter. Caxton Associates LLP acquired a new stake in shares of Definium Therapeutics during the 3rd quarter valued at $126,000. Mercer Global Advisors Inc. ADV boosted its stake in shares of Definium Therapeutics by 10.5% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock worth $259,000 after acquiring an additional 2,079 shares in the last quarter. Finally, Scientech Research LLC acquired a new position in shares of Definium Therapeutics in the 3rd quarter worth $286,000. 27.91% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

DFTX has been the topic of a number of recent analyst reports. HC Wainwright lifted their price objective on shares of Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Piper Sandler reissued an “overweight” rating and set a $48.00 target price (down from $49.00) on shares of Definium Therapeutics in a research note on Friday. Leerink Partners boosted their price target on shares of Definium Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 22nd. Jefferies Financial Group began coverage on shares of Definium Therapeutics in a research note on Thursday, January 29th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Oppenheimer reiterated an “outperform” rating and issued a $40.00 price objective on shares of Definium Therapeutics in a report on Thursday, April 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Definium Therapeutics currently has a consensus rating of “Buy” and an average target price of $37.92.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.